Crinetics Pharmaceuticals (NASDAQ:CRNX) versus Kaya (OTCMKTS:KAYS) Financial Survey

Kaya (OTCMKTS:KAYS) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Risk and Volatility

Kaya has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500.

Insider and Institutional Ownership

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 23.5% of Kaya shares are held by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Kaya and Crinetics Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kaya	N/A	N/A	N/A
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

Analyst Ratings

This is a breakdown of recent ratings for Kaya and Crinetics Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kaya	0	0	0	0	0.00
Crinetics Pharmaceuticals	1	11	5	0	2.24

Crinetics Pharmaceuticals has a consensus target price of $81.00, indicating a potential downside of 4.65%. Given Kaya’s higher probable upside, analysts plainly believe Kaya is more favorable than Crinetics Pharmaceuticals.

Earnings and Valuation

This table compares Kaya and Crinetics Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kaya	$10,000.00	0.00	-$2.08 million	($0.16)	N/A
Crinetics Pharmaceuticals	$7.70 million	1,170.54	-$465.32 million	($5.04)	-16.86

Kaya has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Kaya, indicating that it is currently the more affordable of the two stocks.

Summary

Kaya beats Crinetics Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Kaya

Kaya Holdings, Inc., a vertically integrated legal cannabis enterprise, engages in the operation of psychedelic treatment clinics and medical cannabis dispensaries primarily in the United States. It offers a range of cannabis products, including flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. The company also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, it is involved in the development of a psychedelic treatment center under The Sacred Mushroom name, that provides its guests access to psilocybin treatments, located in Portland, Oregon. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. is headquartered in Fort Lauderdale, Florida.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.